BioMarin to create 50 jobs at Shanbally plant

BioMarin to create 50 jobs at Shanbally plant
Biomarin, Cork

A US biotechnology company is investing $43 million in a new facility in Shanbally that will create more than 50 jobs. BioMarin International Ltd is investing in a new Drug Product Filling Project at its existing facility.

This project will allow the company to meet the rise in demand for its therapies to treat rare genetic diseases that mostly affect children.

A planning application will be submitted in the coming weeks and it is anticipated that an additional 100 personnel will be on site during the construction and commissioning.

The Drug Product Filling Project investment will augment the site’s Drug Substance Manufacturing and Secondary Packaging and Labelling capability.

Since opening its doors in Shanbally in 2011, the company’s workforce has grown to more than 350 employees in Cork, with an additional 55 people based in Dublin and more than 2,600 employees across the world.

Announcing the expansion, the Tánaiste Simon Coveney said BioMarin has thrived in the Cork biopharmaceutical cluster.

“This investment will not only bring opportunities for regional employment but also positive knock-on effects for the local economy.”

BioMarin’s Executive Vice-President, Robert Baffi said: “During our seven years of operations at Shanbally we have seen tremendous growth at the site. This expansion assures that an increasing amount of our commercial products will be manufactured at the site.”

Executive Director of IDA Ireland Mary Buckley said: “I am delighted to welcome BioMarin’s latest investment. As a global leader in the manufacturing of treatments for rare diseases, the company has quickly gone from strength to strength in Ireland. The Shanbally operation is ideally positioned to accommodate this latest expansion due to the existing skill base and the proven track record of success in Cork over the past seven years. Today’s high-value investment in Cork further consolidates Ireland’s position globally as a location of choice for biopharmaceuticals.” 

More in this section

Sponsored Content